Is GE HealthCare (GEHC) overvalued or fairly valued?

MarketChacha shows GE HealthCare's valuation in context — a trailing P/E of about 16.7, a forward P/E of about 12.8, a price-to-book of about 2.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does GE HealthCare's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.07×) from reported figures — education, not a rating.

What is GE HealthCare's revenue?

GE HealthCare reported revenue of $20.6B for FY2025, with net profit of $2.1B, per official filings.

What is the share price of GE HealthCare (GEHC)?

GE HealthCare last traded at $68.86 (-1.2% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

GE HealthCare

GEHC · NASDAQ · Healthcare · United States

Snapshot

TickerGEHC

ExchangeNASDAQ

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees54,000

HeadquartersChicago, United States

Websitewww.gehealthcare.com

Filings tracked17

About GE HealthCare

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Who owns it

Insiders0.4%
Institutions94.2%
Public & other5.5%

1,693 institutional holders

Ownership breakdown from public market data.

Top holders

Dodge & Cox Inc.8.38%
Blackrock Inc.8.30%
Vanguard Capital Management LLC6.58%
State Street Corporation4.62%
Vanguard Portfolio Management LLC4.49%
Invesco Ltd.4.05%
Harris Associates L.P.3.39%
Barrow, Hanley Mewhinney & Strauss, LLC2.98%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.07×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend8.0% → 10.1%

Margin has expanded by about 2.1 points — the business is getting more profitable.

Return on equity20.1%

Latest ROE of 20.1% — capital is generating a healthy return.

Growth qualityrev 3% · PAT 15%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $5.9B · EPS 1.60

Est. earnings growth +10.8%

Next fiscal year

Rev $22.7B · EPS 5.41

Est. earnings growth +9.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$20.6B

Net margin

10.1%

ROE

20.1%

Revenue CAGR (2y)

+2.7%

Profit CAGR (2y)

+15.3%

EPS (FY2025)

4.55

Net profit (FY2025)

$2.1B

Ask MarketChacha about GEHC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about GEHC

Why did Varex Imaging (VREX) jump ~48% today? Teledyne is buying it for $18.90 a share cashc/usmarkets · 8/10/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$20.6B	$2.1B	4.55	10.1%	20.1%
FY2024	$19.7B	$2.0B	4.34	10.1%	23.6%
FY2023	$19.6B	$1.6B	3.03	8.0%	22.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$5.1B	$389.0M	0.85	7.6%
2025Q3	$5.1B	$446.0M	0.98	8.7%
2025Q2	$5.0B	$486.0M	1.06	9.7%
2025Q1	$4.8B	$564.0M	1.23	11.8%
2024Q3	$4.9B	$470.0M	1.02	9.7%
2024Q2	$4.8B	$428.0M	0.93	8.8%
2024Q1	$4.7B	$374.0M	0.81	8.0%
2023Q3	$4.8B	$375.0M	0.82	7.8%
2023Q2	$4.8B	$418.0M	0.91	8.7%
2023Q1	$4.7B	$372.0M	0.41	7.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC7/29/2026material
10-Q filing
SEC7/29/2026
8-K — Reg FD disclosure, Exhibits
SEC7/29/2026material
8-K — Results of operations, Executive/director change, Exhibits
SEC7/23/2026material
8-K — Shareholder vote results, Other events
SEC5/11/2026material
8-K — Results of operations, Exhibits
SEC4/29/2026material
10-Q filing
SEC4/29/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/17/2026material
8-K — Material agreement, Termination of agreement, Material financial obligation, Exhibits
SEC2/27/2026material
8-K — Results of operations, Exhibits
SEC2/4/2026material
10-K filing
SEC2/4/2026

2025

8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC12/15/2025material
8-K — Other events, Exhibits
SEC12/2/2025material
8-K — Results of operations, Exhibits
SEC10/29/2025material
10-Q filing
SEC10/29/2025
8-K — Results of operations, Exhibits
SEC7/30/2025material
10-Q filing
SEC7/30/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.